Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice?
Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice?
复制标题
2 型糖尿病的抗炎治疗是否已准备好用于常规临床实践？
DOI：
10.1038/ncpendmet0645
复制
发表时间：
2007
影响因子：
--
通讯作者：
Nadler,JerryL
中科院分区：
文献类型：
--
作者：
Maybee,NellyA;Worrall,BradfordB;Nadler,JerryL
背景2型糖尿病（T2 DM）是以胰腺功能进行性丧失为特征的疾病，其部分原因是β细胞凋亡增加。炎症细胞因子白细胞介素1β（IL-1β）是细胞凋亡的一个假定的介导者，目的评价重组IL-1受体拮抗剂（阿那白滞素）作为T2 DM治疗新方法的疗效。
BackgroundType 2 diabetes mellitus (T2DM) is characterized by a progressive loss of pancreatic function, which results in part from increased β-cell apoptosis. The inflammatory cytokine interleukin 1β (IL-1β) is a putative mediator of apoptosis in this context.ObjectiveTo evaluate the efficacy of a recombinant IL-1-receptor antagonist (anakinra) as a novel therapy for T2DM.